Childhood factors associated with asthma remission after 30 year follow up

Vonk, J. M.; Posima, D. S.; Boezen, H. M.; Grol, M. H.; Schoulen, J. P.; Koëter, G. H.; Gerritsen, J.
November 2004
Thorax;Nov2004, Vol. 59 Issue 11, p925
Academic Journal
Background: Factors contributing to either "complete" or "clinical" remission of asthma are important to know since there is no cure for the disease. Methods: A cohort of 119 allergic asthmatic children was examined three times with a mean follow up of 30 years. They were aged 5-14 years at visit 1 (1966-9), 21-33 years at visit 2 (1983-6), and 32-42 years at visit 3 (1995-6). Complete remission of asthma at visit 3 was defined as no asthma symptoms, no use of inhaled corticosteroids, normal lung function (FEY1 <90% predicted), and no bronchial hyperresponsiveness (PC10 <16 mg/ml). Clinical remission was defined as no asthma symptoms and no use of inhaled corticosteroids. Results: 22% of the group was in complete remission of asthma at visit 3 and a further 30% was in clinical remission (total 52%); 57% of subjects in clinical remission had bronchial hyperresponsiveness and/or a low lung function. Logistic regression analyses showed that a higher FEY1 in childhood and more improvement in FEY1 from age 5-14 to 21-33 were associated with both complete and clinical asthma remission at age 32-42. Conclusions: Complete remission of asthma was present in a small subset of asthmatics while half the subjects showed clinical remission. Both complete and clinical remission were associated with a higher lung function level in childhood and a higher subsequent increase in FEY1. These results support the view that defining remission only on the basis of symptoms and medication use will overlook subjects with subclinical active disease and possibly associated airway remodelling.


Related Articles

  • When can personal best peak flow be determined for asthma action plans? Reddel, H. K.; Marks, G. B.; Jenkins, C. R. // Thorax;Nov2004, Vol. 59 Issue 11, p922 

    Background: Written asthma action plans based on personal best peak expiratory flow (PEF) consistently improve health outcomes, whereas those based on predicted PEF do not. Guidelines state that personal best PEF should be assessed over 2-3 weeks during good asthma control, but it is unclear how...

  • Unexpected Results From a Well-Known Remedy. Schaffer, Rodney // American Journal of Homeopathic Medicine;Summer2005, Vol. 98 Issue 2, p99 

    A boy with asthma is treated with the well-known polychrest Pulsatilla with some unexpected results. This boy's initial symptomatology included 'dreams of fire' fear of fire: and `fear of robbers: While these symptoms are not historically associated with Pulsatilla, they responded to the remedy...

  • Bronchial Asthma: New Definition for an Old Disease. Samter, Max // Clinical Pediatrics;May1974, Vol. 13 Issue 5, p406 

    The article presents a definition of asthma. Standard textbooks of medicine have described asthma, but have not defined it. Symptoms or manifestations mentioned include wheezing, dyspnea, shortness of breath, intermittent, recurrent, seasonal, or perennial. Much evidence begins to support the...

  • Respiratory symptoms in adults are related to impaired quality of life, regardless of asthma and COPD: results from the European community respiratory health survey. Voll-Aanerud, Marianne; Eagan, Tomas M. L.; Plana, Estel; Omenaas, Ernst R.; Bakke, Per S.; Svanes, Cecilie; Siroux, Valerie; Pin, Isabelle; Antó, Josep M.; Leynaert, Benedicte // Health & Quality of Life Outcomes;2010, Vol. 8, p107 

    Background: Respiratory symptoms are common in the general population, and their presence is related to Health-related quality of life (HRQoL). The objective was to describe the association of respiratory symptoms with HRQoL in subjects with and without asthma or COPD and to investigate the role...

  • Comparative Efficacy of Budesonide by Different Delivery Devices in Bronchial Asthma. Rizvi, Dilshad Ali; Salman, Mohammad Tariq; Mahmood, Syed Esam; Sircar, Joydeep; Ansari, Karim Ullah; Verma, Vinod Kumar // National Journal of Physiology, Pharmacy & Pharmacology;2012, Vol. 2 Issue 2, p99 

    Aims& Objective: To assess the relative efficiency of budesonide administered from different delivery devices to adult patients of chronic stable bronchial asthma as measured by pulmonary function test parameters. Materials and Methods: This prospective study was undertaken to assess the...

  • asthma:. Huber, Jeffrey T.; Gillaspy, Mary L. // Encyclopedic Dictionary of AIDS-Related Terminology;2000, p32 

    The article presents an encyclopedia entry for asthma. It refers to a condition in which periodically recurring sudden attacks of difficulty in breathing are accompanied by coughing and wheezing. Asthma is also known as a condition manifested by paroxysmal shortness of breath accompanied by...

  • Genetic basis of asthma. Jindal, Surinder K. // Indian Journal of Medical Research;Dec2015, Vol. 142 Issue 6, p640 

    The author discusses the genetic basis of asthma. He says that asthma is a chronic inflammatory disease which impact individuals of all age groups. He adds that about half of the patients of asthma have genetic susceptibility. He mentions that the presence of a family history of asthma and/or...

  • The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Zanini, Andrea; Chetta, Alfredo; Imperatori, Andrea S.; Spanevello, Antonio; Olivieri, Dario // Respiratory Research;2010, Vol. 11, p132 

    In recent years, there has been increased interest in the vascular component of airway remodelling in chronic bronchial inflammation, such as asthma and COPD, and in its role in the progression of disease. In particular, the bronchial mucosa in asthmatics is more vascularised, showing a higher...

  • Outcomes in Clinical Trials of Inhaled Corticosteroids for Children with Asthma Are Narrowly Focussed on Short Term Disease Activity. Sinha, Ian P.; Williamson, Paula R.; Smyth, Rosalind L. // PLoS ONE;2009, Vol. 4 Issue 7, p1 

    Background: Little work has been done to determine which outcomes should be measured in randomised controlled trials (RCTs) in children with asthma. Drug regulatory authorities require that short term disease activity is measured, but other outcome domains are not mandatory for licensing and...


Read the Article


Sign out of this library

Other Topics